Four touch down in Enzo
This article was originally published in Scrip
Enzo Life Sciences, a subsidiary of Enzo Biochem, has appointed four executives to newly created positions: Dr Bruce Taillon from Roche Diagnostics' 454 Life Sciences Division joins as head of global technology business development; Dr John D'Errico will lead the company's commercial merchandising operations and previously served at VWR Scientific; Kara Cannon joins as head of global marketing after ten years at Pall Corporation; and Dr Paul Munger, previously an executive at Pierce Chemical, joins to lead Enzo's global manufacturing operations.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.